Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
Acute therapies continue to report strong growth compared to chronic ones.
This unique record was made possible by collating hard copies of the books in a structured manner
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
At present 18 per cent of the local pharmaceutical market is under government's price control
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Filing for WHO Emergency Use Authorisation this month
It is designed to tackle mental health issues
Subscribe To Our Newsletter & Stay Updated
